HC Wainwright

In a report published Monday, H.C. Wainwright analyst Heiko F. Ihle assumed coverage of Energy Fuels Inc Ordinary Shares (Canada) (NYSE: UUUU) with a Buy rating and a price target of $6.30, after the completion of the acquisition of Uranerz Energy Corp (NYSE: URZ). The acquisition, which closed on...

In a report published Tuesday, HC Wainwright analyst Ching-Yi Lin initiated coverage of CASI Pharmaceuticals Inc (NASDAQ: CASI) with a Buy rating and a price target of $2.50. Casi is a clinical stage company focused on developing and commercializing oncology therapeutics for both the US and Chinese...

In a report published Monday, HC Wainwright analyst Mark Breidenbach initiated coverage of OncoSec Medical Inc (NASDAQ: ONCS) with a Buy rating and a price target of $25. The target price reflects the recent 20-for-1 reverse stock split, which reduced the total outstanding shares of common stock...

In a report published Wednesday, HC Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on RedHill Biopharma Ltd - ADR (NASDAQ: RDHL), while raising the price target from $23 to $32. The company announced on Tuesday that it had received UK regulatory approval to initiate the Phase 3...

The American Society of Clinical Oncology (ASCO) conference is wrapping up in Chicago. The three day conference brings together thousands of oncology professionals and pharmaceutical companies to share research and new best practices. H.C. Wainwright analyst Reni Benjamin attended several...

In a report published Monday, HC Wainwright analysts initiated coverage of StemCells Inc (NASDAQ: STEM) with a Buy rating and a price target of $1. StemCells is carrying out clinical tests to apply its human CNS stem cells platform for developing treatments for CNS disorders. "The company...

HC Wainwright initiated coverage on Flex Pharma, Inc. (NASDAQ: FLKS) with a Buy rating. The target price for Flex Pharma is set to $40. Flex Pharma shares closed at $19.46 yesterday.

Analysts at HC Wainwright initiated coverage on Redhill Biopharma Ltd. (NASDAQ: RDHL) with a Buy rating. The target price for Redhill Biopharma is set to $23. Redhill Biopharma shares have dropped 0.29% over the past 52 weeks, while the S&P 500 index has surged 11.47% in the same period....

Analysts at HC Wainwright initiated coverage on Finjan Holdings (NASDAQ: FNJN) with a Buy rating. The target price for Finjan Holdings is set to $5. Finjan shares have dropped 55.43% over the past 52 weeks, while the S&P 500 index has gained 17.64% in the same period. Finjan Holdings' shares...

Vertex Pharmaceuticals (NASDAQ: VRTX) reported earnings after the bell on Tuesday, July 29, that beat consensus estimates. Despite the beat, the stock declined in Wednesday's trading action by 3.73 percent. Credit Suisse reiterated a Neutral rating, $94 price target: “VRTX reported non-GAAP EPS...

HC Wainwright cut its rating on Vertex Pharmaceuticals (NASDAQ: VRTX) to Neutral after the stock rallied nearly 50 percent Tuesday. Analyst Andrew Fein started, “VRTX shares are finally appropriately valued.” Regarding VX-809’s commercialization, Fein shares his concerns:...